Clinical Trial: A Phase Ib/II Study of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07629778) titled 'A Phase Ib/II Study of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis' on June 01.

Brief Summary: This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.

Study Start Date: May 11

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis

Intervention: DRUG: HL-300

Group A receives the investigational product at a concentration of 0.25%, Group B at 0.5%, and Group C at 1.0%, BID,4 weeks.

DRUG: Placebo

BID, day 7.

Recr...